C

Citius Oncology Inc
NASDAQ:CTOR

Watchlist Manager
Citius Oncology Inc
NASDAQ:CTOR
Watchlist
Price: 1.99 USD 5.29% Market Closed
Market Cap: 156m USD

Intrinsic Value

The intrinsic value of one CTOR stock under the Base Case scenario is 6.6 USD. Compared to the current market price of 1.99 USD, Citius Oncology Inc is Undervalued by 70%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CTOR Intrinsic Value
6.6 USD
Undervaluation 70%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation History
Citius Oncology Inc

What is Valuation History?
Compare CTOR to

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CTOR?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Citius Oncology Inc
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Citius Oncology Inc

Balance Sheet Decomposition
Citius Oncology Inc

Current Assets 18.3m
Other Current Assets 18.3m
Non-Current Assets 73.4m
Intangibles 73.4m
Efficiency

Free Cash Flow Analysis
Citius Oncology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Citius Oncology Inc

Revenue
0 USD
Operating Expenses
-38.8m USD
Operating Income
-38.8m USD
Other Expenses
-3m USD
Net Income
-41.8m USD
Fundamental Scores

CTOR Profitability Score
Profitability Due Diligence

Citius Oncology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
Negative ROE
26/100
Profitability
Score

Citius Oncology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

CTOR Solvency Score
Solvency Due Diligence

Citius Oncology Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
44/100
Solvency
Score

Citius Oncology Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CTOR Price Targets Summary
Citius Oncology Inc

Wall Street analysts forecast CTOR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTOR is 3.06 USD with a low forecast of 3.03 USD and a high forecast of 3.15 USD.

Lowest
Price Target
3.03 USD
52% Upside
Average
Price Target
3.06 USD
54% Upside
Highest
Price Target
3.15 USD
58% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Citius Oncology Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CTOR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CTOR stock?

The intrinsic value of one CTOR stock under the Base Case scenario is 6.6 USD.

Is CTOR stock undervalued or overvalued?

Compared to the current market price of 1.99 USD, Citius Oncology Inc is Undervalued by 70%.

Back to Top